Cited by 338Fullerene Chemistry and ApplicationsParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Fullerene-based antioxidants and neurodegenerative disorders.

Dugan, L.L., Lovett, E.G., Quick, K.L., Lotharius, J., Lin, T.T., O'Malley, K.L.·2001·Parkinsonism & Related Disorders

Abstract

Water-soluble derivatives of buckminsterfullerene (C(60)) derivatives are a unique class of compounds with potent antioxidant properties. Studies on one class of these compounds, the malonic acid C(60) derivatives (carboxyfullerenes), indicated that they are capable of eliminating both superoxide anion and H(2)O(2), and were effective inhibitors of lipid peroxidation, as well. Carboxyfullerenes demonstrated robust neuroprotection against excitotoxic, apoptotic and metabolic insults in cortical cell cultures. They were also capable of rescuing mesencephalic dopaminergic neurons from both MPP(+) and 6-hydroxydopamine-induced degeneration. Although there is limited in vivo data on these compounds to date, we have previously reported that systemic administration of the C(3) carboxyfullerene isomer delayed motor deterioration and death in a mouse model of familial amyotrophic lateral sclerosis (FALS). Ongoing studies in other animal models of CNS disease states suggest that these novel antioxidants are potential neuroprotective agents for other neurodegenerative disorders, including Parkinson's disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1353-8020(00)00064-x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Cited by

Sorted by citations

Items 101–200 of 337

Metadata

Authors
Dugan, L. L., Lovett, E. G., Quick, K. L., Lotharius, J., Lin, T. T., & O'Malley, K. L.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Dugan, L.L.
Venue
Parkinsonism & Related Disorders
Publisher
Elsevier BV
Published
2001-07
Volume
7
Issue
3
Pages
243-246
ISSN
1353-8020 (ISSN-L)
OpenAlex
W2126036130
Cited by
338
References
9
Citations by year
2026: 3 · 2025: 6 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 14 · 2020: 20 · 2019: 14 · 2018: 13 · 2017: 9 · 2016: 10 · 2015: 14 · 2014: 15 · 2013: 12 · 2012: 22
FWCI
4.57
Type
journal article
Language
en
Open access
closed
Locations
  • Parkinsonism & Related Disorders (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Fullerene Chemistry and Applications
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review